Intravenous methylprednisolone is a potential add on therapy for Ring chromosome 20 syndrome

Vyasaraj Kalya Kishore; Lakshminarayanapuram Gopal Viswanathan; Ajay Asranna; Raghavendra Kenchiah; Ravindranadh Chowdary M; Sanjib Sinha

doi:10.1016/j.seizure.2022.01.018

Intravenous methylprednisolone is a potential add on therapy for Ring chromosome 20 syndrome

Seizure. 2022 Mar:96:118-120. doi: 10.1016/j.seizure.2022.01.018. Epub 2022 Feb 5.

Authors

Vyasaraj Kalya Kishore¹, Lakshminarayanapuram Gopal Viswanathan¹, Ajay Asranna¹, Raghavendra Kenchiah¹, Ravindranadh Chowdary M¹, Sanjib Sinha²

Affiliations

¹ Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
² Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India. Electronic address: [email protected].

PMID: 35196643
DOI: 10.1016/j.seizure.2022.01.018

Abstract

Ring 20 syndrome is a rare cause of refractory epilepsy and non-convulsive status epilepticus in children. We report a patient with Ring 20 syndrome with refractory focal seizures and non-convulsive status epilepticus who showed good treatment response with intravenous steroids. We wish to highlight that intravenous pulse methylprednisolone is a useful treatment strategy in this setting.

Keywords: Methyl prednisolone; Non-convulsive status epilepticus; Ring 20.

Publication types

Case Reports

MeSH terms

Child
Humans
Methylprednisolone / therapeutic use
Ring Chromosomes*
Seizures / complications
Seizures / drug therapy
Status Epilepticus* / etiology

Substances

Methylprednisolone

Supplementary concepts

Ring Chromosome 20 Syndrome